Zacks: Analysts Anticipate Ultragenyx Pharmaceutical Inc (RARE) Will Announce Quarterly Sales of $21.19 Million Posted by Maurice Goldstein on May 17th, 2019
Equities research analysts forecast that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post sales of $21.19 million for the current fiscal quarter, according to Zacks . Seven analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with the lowest sales estimate coming in at $19.09 million and the highest estimate coming in at $22.77 million. Ultragenyx Pharmaceutical reported sales of $12.79 million in the same quarter last year, which indicates a positive year-over-year growth rate of 65.7%. The business is scheduled to issue its next earnings report on Thursday, August 1st.
On average, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $95.26 million for the current year, with estimates ranging from $87.10 million to $103.26 million. For the next financial year, analysts anticipate that the firm will post sales of $198.98 million, with estimates ranging from $142.10 million to $248.64 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Ultragenyx Pharmaceutical. Get Ultragenyx Pharmaceutical alerts: Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 51.00% and a negative net margin of 550.30%. The business had revenue of $18.17 million for the quarter, compared to analysts’ expectations of $18.75 million. During the same period last year, the business earned $0.63 EPS. The company’s revenue for the quarter was up 70.1% on a year-over-year basis. Several analysts recently commented on the stock. Barclays restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, May 9th. ValuEngine lowered shares of Ultragenyx Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 8th. Wedbush restated an “outperform” rating and set a $77.00 price target (down previously from $88.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, May 7th. BidaskClub lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Finally, Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $73.00 price target on the stock in a research report on Tuesday, April 23rd. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $78.65.
In other news, EVP Karah Herdman Parschauer sold 468 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $68.30, for a total value of $31,964.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website . Also, CFO Shalini Sharp sold 14,800 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $70.00, for a total transaction of $1,036,000.00. The disclosure for this sale can be found here . 8.40% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in RARE. Exane Derivatives acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $36,000. Meeder Asset Management Inc. grew its position in shares of Ultragenyx Pharmaceutical by 321.1% in the first quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 456 shares during the period. Bank of Montreal Can grew its position in shares of Ultragenyx Pharmaceutical by 100.9% in the fourth quarter. Bank of Montreal Can now owns 1,079 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 542 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $55,000. Finally, First Mercantile Trust Co. grew its position in shares of Ultragenyx Pharmaceutical by 101.0% in the first quarter. First Mercantile Trust Co. now owns 985 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 495 shares during the period. Institutional investors and hedge funds own 88.62% of the company’s stock. Shares of Ultragenyx Pharmaceutical stock opened at $63.46 on Friday. The firm has a market cap of $3.65 billion, a P/E ratio of -8.59 and a beta of 2.14. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.77 and a quick ratio of 11.60. Ultragenyx Pharmaceutical has a 1 year low of $37.44 and a 1 year high of $90.98.
Ultragenyx Pharmaceutical Company Profile.
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.